10x (TXG) - Long-Term Debt to Capital

Symbol and logo of brand 10x (TXG)

10x Genomics, Inc. (TXG) is implementing eco-friendly synthesis methods and biodegradable packaging, yet a reduction in research grants and intensifying competition are eroding its pricing power. This price chart demonstrates that the individual long-term debt-to-equity ratio stands at 0.08. The stability of 10x Genomics, Inc. (TXG) relies on demand from pharma behemoths for cell analysis equipment and robust patent protection.

TXG: 10x Long-Term Debt to Equity Ratio 07/04/2022 - 10/30/2026

Comprehensive metric breakdowns and analytics for 10x Genomics, Inc. (TXG)

- current price and projected stock value:
Share Price 10x Genomics Inc|TXG - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization 10x Genomics, Inc.|TXG - Enterprise Value
- company book value details:
Book Price of a Share 10x Genomics|TXG - Company Net Assets|Capitalization to Book Value Ratio 10xgenomics.com|TXG - Cumulative Company Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio 10x Genomics, Inc.|TXG - Long-Term Debt to Capital|Short-Term Indebtedness to Equity 10xgenomics.com|TXG - Company Aggregate Debts|Debts to Book Value 10x Genomics, Inc.|TXG - Company Long-Term Debt|Company Short-Term Indebtedness 10x Genomics|Immediate Liquidity 10xgenomics.com
- earnings and valuation multiples information:
TXG - Company Net Income
Summary company analysis:TXG (10x Genomics Inc)
Flagship merchandise of 10x Genomics, Inc.

This indicator measures the proportion of long-term liabilities within the equity structure, allowing for an assessment of the company's resilience to credit risks and the efficiency of its financial leverage. Analyzing the long-term debt-to-equity ratio is critically important for 10x Genomics, Inc. (TXG), as export restrictions in Asia could reduce revenue, turning excessive debt loads into a factor of systemic instability.

Analysis of competing companies

Long-Term Debt to Capital Ratio TEM (Tempus)|Long-Term Debt to Capital QGEN|Long-Term Debt to Capital Isis Pharmaceuticals (IONS)|Long-Term Debt to Capital RGEN (Repligen Corporation)|Long-Term Loans to Capital Ratio RNA (aviditybiosciences.com)|CRSP: Long-Term Debt to Equity Ratio|WGS (GeneDx Holdings) - Long-Term Debt to Capital Ratio|RARE (Ultragenyx Pharma) - Long-Term Debt to Equity Ratio|Beam Tx - Long-Term Debt to Capital Coefficient|SRPT (Sarepta Therapeutics, Inc.) - Long-Term Debt to Capital|TWST - Long-Term Indebtedness to Equity|Long-Term Debt to Capital NTLA|STOK - Long-Term Liabilities to Capital|Long-Term Debt to Equity BioLife Corp BLFS|WVE: Long-Term Debt to Capital Ratio|MAZE - Long-Term Debt to Equity|Long-Term Liabilities to Capital sionnatx.com|Prime Medicine (PRME) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Taysha Gene Therapies Inc|QURE (uniQure Corp) - Long-Term Debt to Capital|MeiraGTx Corp (MGTX) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital RGNX|Long-Term Debt to Equity Ratio solidbio.com SLDB|Long-Term Debt to Equity Ocugen OCGN|Ratio of Long-Term Indebtedness to Capital Pacific Biosciences of California, Inc. (PACB)|BNTC: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient DSGN (Design Corp)|RCKT: Long-Term Debt to Capital|FDMT - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Lexeo Therapeutics Inc.|Long-Term Debt to Capital Ratio KRRO (Korro Bio, Inc)|Long-Term Debt to Capital EDIT|Long-Term Debt to Equity Ratio Silence Therapeutics Corp SLN|ProQR Therapeutics - Long-Term Debt to Equity Ratio|Ratio of Long-Term Indebtedness to Capital Codexis Inc (CDXS)|SGMO: Long-Term Debt to Equity Ratio|Nautilus Biotechnology - Long-Term Loans to Capital Ratio|MGX (Metagenomi, Inc) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Ratio DTIL|GBIO (Generation Bio Co) - Long-Term Debt to Capital|BOLD - Long-Term Indebtedness to Equity|Long-Term Debt to Capital XCUR|imunon.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Equity Phio Pharmaceuticals Corp. PHIO|MBIO: Long-Term Debt to Capital Ratio|TransCode - Long-Term Debt to Capital|BNGO - Long-Term Debt to Capital|APDN: Long-Term Debt to Capital|BLUE: Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Ratio IPA|Long-Term Debt to Capital Ratio OMGA (Omega Therapeutics Corp)|Long-Term Debt to Equity Ratio OMIC (Singular Genomics Systems)|RGLS (regulusrx.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital SYRS (Syros Pharmaceuticals, Inc.)|Long-Term Indebtedness to Equity Telesis Bio Inc.|TRACON - Long-Term Debt to Capital|Long-Term Liabilities to Capital Unity Biotechnology, Inc